These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38123578)

  • 1. Author Correction: The unusual quadruple bonding of nitrogen in ThN.
    Fei Z; Wang JQ; Tang R; Lu Y; Han C; Wang Y; Hong J; Dong C; Hu HS; Xiong XG; Ning C; Liu H; Li J
    Nat Commun; 2023 Dec; 14(1):8471. PubMed ID: 38123578
    [No Abstract]   [Full Text] [Related]  

  • 2. The unusual quadruple bonding of nitrogen in ThN.
    Fei Z; Wang JQ; Tang R; Lu Y; Han C; Wang Y; Hong J; Dong C; Hu HS; Xiong XG; Ning C; Liu H; Li J
    Nat Commun; 2023 Nov; 14(1):7677. PubMed ID: 37996410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boron-boron quadruple bond in Li
    Kalita AJ; Rohman SS; Kashyap C; Ullah SS; Baruah I; Mazumder LJ; Das K; Guha AK
    Phys Chem Chem Phys; 2021 Sep; 23(37):20985-20988. PubMed ID: 34519306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who is using take-home naloxone? An examination of supersavers.
    Eide D; Lobmaier P; Clausen T
    Harm Reduct J; 2022 Jun; 19(1):65. PubMed ID: 35717240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "It can save your life, that's all I know," barriers and facilitators for engagement in take-home naloxone for people receiving opioid substitution treatment in regional Australia: An explorative study.
    Natale I; Harvey C; Wood P; Anderson K
    Qual Res Med Healthc; 2023 Jul; 7(2):10868. PubMed ID: 37692452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rethinking 'carriage' of take-home naloxone.
    McDonald R; Parkin S; Eide D; Neale J; Clausen T; Metrebian N; Carter B; Strang J
    Int J Drug Policy; 2021 Sep; 95():103253. PubMed ID: 33848942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadruple bonding between iron and boron in the BFe(CO)
    Chi C; Wang JQ; Hu HS; Zhang YY; Li WL; Meng L; Luo M; Zhou M; Li J
    Nat Commun; 2019 Oct; 10(1):4713. PubMed ID: 31624260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study protocol for a European, mixed methods, prospective, cohort study of the effectiveness of naloxone administration by community members, in reversing opioid overdose: NalPORS.
    Metrebian N; Carter B; Eide D; McDonald R; Neale J; Parkin S; Dascal T; Mackie C; Day E; Guterstam J; Horsburgh K; Kåberg M; Kelleher M; Smith J; Thiesen H; Strang J
    BMC Public Health; 2023 Aug; 23(1):1608. PubMed ID: 37612698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injection Drug Use Frequency Before and After Take-Home Naloxone Training.
    Colledge-Frisby S; Rathnayake K; Nielsen S; Stoove M; Maher L; Agius PA; Higgs P; Dietze P
    JAMA Netw Open; 2023 Aug; 6(8):e2327319. PubMed ID: 37540514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Take-Home Naloxone and risk management from the perspective of people who survived an opioid overdose in Stockholm - An analysis informed by drug, set and setting.
    Holmén E; Hammarberg A; Kåberg M; Storbjörk J
    Int J Drug Policy; 2023 May; 115():104021. PubMed ID: 37011507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with take-home naloxone kit usage in British Columbia: an analysis of administrative data.
    Lei V; Ferguson M; Geiger R; Williams S; Liu L; Buxton JA
    Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):25. PubMed ID: 35361228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Take-Home Naloxone Kits: Attitudes and Likelihood-Of-Use Outcomes from a European Survey of Potential Overdose Witnesses.
    McDonald R; Breidahl S; Abel-Ollo K; Akhtar S; Clausen T; Day E; Kelleher M; McAuley A; Petersen H; Sefranek M; Thiesen H; Strang J
    Eur Addict Res; 2022; 28(3):220-225. PubMed ID: 35114666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proportion and conditions of use of intranasal take-home naloxone kits: A retrospective study in two French outpatient addiction centers, 2016-2020.
    Chappuy M; Fezzani L; Ragonnet D; Berger-Vergiat A; Duvernay N; Lack P; Rolland B
    Therapie; 2022; 77(5):581-584. PubMed ID: 35086690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.
    Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N
    Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catch Me if You Can: the Crosstalk of Zika Virus and the Restriction Factor Tetherin.
    Herrlein ML; Schmanke P; Elgner F; Sabino C; Akhras S; Bender D; Glitscher M; Tabari D; Scholl C; Stingl J; Hildt E
    J Virol; 2022 Feb; 96(4):e0211721. PubMed ID: 34935441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and meta-analysis of the prevalence of take-home naloxone (THN) ownership and carriage.
    Burton G; McAuley A; Schofield J; Yeung A; Matheson C; Parkes T
    Int J Drug Policy; 2021 Oct; 96():103298. PubMed ID: 34078563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for Take-home naloxone In Multicentre Emergency (TIME) settings: feasibility study.
    Jones M; Bell F; Benger J; Black S; Buykx P; Dixon S; Driscoll T; Evans B; Edwards A; Fuller G; Goodacre S; Hoskins R; Hughes J; John A; Jones J; Moore C; Sampson F; Watkins A; Snooks H
    Pilot Feasibility Stud; 2020; 6():96. PubMed ID: 32670598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD.
    Dayton L; Gicquelais RE; Tobin K; Davey-Rothwell M; Falade-Nwulia O; Kong X; Fingerhood M; Jones AA; Latkin C
    PLoS One; 2019; 14(11):e0224686. PubMed ID: 31697736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient characteristics associated with being offered take home naloxone in a busy, urban emergency department: a retrospective chart review.
    O'Brien DC; Dabbs D; Dong K; Veugelers PJ; Hyshka E
    BMC Health Serv Res; 2019 Sep; 19(1):632. PubMed ID: 31488142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.